Patient Centered Health Management®
Patient-centered. Health focused.
We're dedicated to minimizing the impact of ultra-orphan diseases and maximizing the quality of life of patients who face them. Addressing the challenges of these patients is unlike any other opportunity within the pharmaceutical industry. That's why, unlike most other pharmaceutical organizations, Centric Health Resources is solely focused on the specific needs of this unique patient population. As the only company specializing in this important niche, we have vast expertise from years of valuable experience.
To best serve these patients and their families, we have developed and implemented our Patient Centered Health Management® service model. This comprehensive approach is designed to cover virtually all health care aspects of patients' lives and seamlessly combines the positive synergies of patient advocacy groups, clinicians, health care payers and biopharmaceutical companies. We carefully and proactively monitor prescribed therapies and specialized health management services to ultra-orphan patients. In addition, we empower members of the chronic community with relationship-driven opportunities that bridge the comprehensive care gap, provide direct peer support and help the Centric team to ensure patient compliance, improve overall health outcomes, upgrade quality of life and lower the ongoing costs associated with a lifetime of chronic care.
The ultimate outcome is an overall reduction in the patients' lifelong cost of care - and an increase in patient quality of life. Our treatment-program patients receive financial reimbursement services and we educate health benefit providers with effective methods of managing the high cost of these therapies. All of these efforts are focused on the real reason we're all here in the first place - our valued patients.
Centric Health Resources is the exclusive provider of the PROLASTIN DIRECT® program for patients with alpha-1 antitrypsin deficiency in the United States. We are proud to care for the largest identified group of patients with alpha-1 in the U.S. through this program.
Watch The Prolastin Direct Story
to learn more: